Novo Nordisk stock faces FDA vision warning amid recovery test
Published on 11/10/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew safety issue meets recovery hopes
- The FDA ordered updated prescribing information for Ozempic and Wegovy over the rare eye condition NAION.
- Novo Nordisk said its benefit-risk profile remains favorable as investors monitor prescriptions and refills.
- The company still expects 2026 adjusted sales and operating profit growth between minus 2 percent and plus 2 percent at constant exchange rates.
Novo Nordisk stock faces a new regulatory issue as the U.S. Food and Drug Administration ordered updated prescribing information for Ozempic and Wegovy over a rare eye condition that can cause sudden vision loss. The development adds a safety focus to the recovery case built around stronger Wegovy pill demand and a higher 2026 outlook.
According to Yahoo Finance, the FDA is requiring manufacturers to update labels for non-arteritic anterior ischemic optic neuropathy, or NAION. The agency review covered 126 clinical trials and found 6.4 probable cases per 100,000 person-years among patients taking GLP-1 drugs, compared with 3.8 cases among patients receiving a placebo or another diabetes medicine.
Safety risk enters recovery debate
The FDA advised patients with sudden vision changes in one eye to contact a health care professional immediately. Novo Nordisk said it remained confident in the benefit-risk profile of its medicines, while Citi analyst Geoff Meacham told Reuters that the rarity of the condition and the benefits of treatment could limit changes in prescribing.
For investors, the commercial test will be whether revised labels affect new prescriptions or refills. That question arrives as Novo Nordisk works to rebuild momentum against intense competition in obesity treatment.
Wegovy pill supports higher outlook
Novo Nordisk raised its 2026 adjusted sales and operating profit outlook on November 4 to a range of minus 2 percent to plus 2 percent at constant exchange rates, from a previous range of minus 6 percent to zero. Third-quarter adjusted sales rose 4 percent at constant exchange rates, while adjusted operating profit increased 27 percent on the same basis. Wegovy pill sales reached DKK 5.394 billion in the quarter.
Novo Nordisk stock traded at 36.28 euros on Lang & Schwarz at 17:05 CET on Tuesday, November 10, 2026.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Lang & Schwarz price: EUR 36.28 at 17:05 CET on November 10, 2026
- 2026 adjusted outlook: Sales and operating profit growth of minus 2 percent to plus 2 percent at constant exchange rates
- Third-quarter Wegovy pill sales: DKK 5.394 billion
European investors are also weighing health care and pharmaceutical risk across the broader market environment.
